UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Nevada 33-2382547 Identification No.) Gr ...

Company Overview - PMGC Holdings Inc. has completed the acquisition of AGA Precision Systems LLC, a CNC machining business based in California, which generated over $1.39 million in revenue in 2024 and has a history of profitability [1][4] - The acquisition aligns with PMGC's strategy of acquiring U.S.-based, cash-flow-positive industrial businesses to strengthen mission-critical supply chains [1][5] - AGA will continue operations under its existing leadership with support from PMGC's management team [3] Strategic Rationale - The acquisition of AGA is part of PMGC's broader strategy to acquire specialized manufacturing businesses with strong fundamentals and long-term growth potential [5] - AGA's expertise in specialty metals and its established customer relationships enhance PMGC's operational and strategic value [6] - PMGC plans to support AGA's growth through investments in business development and production efficiency [6] Industry Outlook - The global CNC machine tool market is projected to grow from $100.5 billion in 2024 to $109.1 billion in 2025, with expectations to exceed $200 billion by 2033 [7] - Growth in the CNC machine tool market is driven by demand from aerospace, defense, and industrial sectors, along with reshoring efforts supported by recent legislation [7] Recent Acquisitions - AGA marks PMGC's second acquisition in the quarter, following the acquisition of Pacific Sun Packaging on July 10, 2025 [8] - The acquisition of AGA adds $1.39 million in cash-flow-positive revenue, bringing PMGC's estimated total annualized revenue to over $2.25 million [9][10]

Core Insights - Pacific Sun Packaging Inc., a subsidiary of PMGC Holdings Inc., is participating in the 2025 ITAD Summit in Las Vegas, marking its first appearance at the event [1] - The company specializes in high-precision, component-specific packaging solutions for IT and electronics hardware, catering to OEMs, data centers, and ITAD firms [1][4] - The CEO emphasized the importance of technical and critical packaging needs in the evolving ITAD and data center industries [2] Company Overview - Founded in 2011, Pacific Sun Packaging focuses on custom-engineered solutions to protect delicate IT components such as CPUs, DIMMs, SSDs, HDDs, and fiber-optic modules [1][4] - The company's packaging solutions are designed to meet rigorous standards for ESD safety, dimensional precision, and supply chain durability [1] - Pacific Sun Packaging is headquartered in San Clemente, California, and is known for its fast design cycles and scalable production capabilities [2][4] Industry Context - The ITAD and data center industries are experiencing evolving packaging needs that are becoming more technical and critical [2] - The summit provides an opportunity for the company to reconnect with existing customers and build relationships with new partners in IT lifecycle management [2] - The company's tailored packaging strategies aim to enhance resale value, reduce returns, and streamline integration [2]

Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC’s exposure to U.S. semiconductor and artificial intelligence (“AI”) infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company,” “PMGC,” “we,” or “us”), a diversified public hol ...

Core Viewpoint - PMGC Holdings Inc. has entered into a non-binding Letter of Intent to acquire a U.S.-based CNC machining company specializing in high-complexity components for the aerospace and defense sectors [1] About the Target Company - The target company, founded in 1948, is AS9100 and ISO 9001 certified, specializing in precision aerospace components [2] - It operates a modern facility equipped with 5-axis CNC machines and advanced CAD/CAM and ERP systems, offering a full range of secondary services including grinding, EDM, and honing [2] - The company serves commercial and defense aerospace customers, delivering high-quality parts with ultra-tight tolerances and cleanroom-capable production [2] Financial Overview - The target company reported a revenue of approximately $4.5 million and an adjusted EBITDA of $500,000 for 2024, indicating consistent profitability [3] - Its growth has been entirely organic, relying on customer referrals, repeat business, and trusted vendor relationships [3] Strategic Fit - This acquisition aligns with PMGC's strategy to acquire specialized U.S. manufacturers in sectors where quality and technical expertise are crucial [4] - The aerospace sector is experiencing increased demand for certified domestic suppliers due to federal incentives and geopolitical factors promoting onshoring and supply chain resiliency [4] Management Perspective - PMGC's CEO highlighted the target company's integration into high-trust aerospace supply chains and its consistent earnings as key factors making it a natural fit for PMGC's platform [5] - The closing of the acquisition is subject to customary conditions, including due diligence and corporate approvals [5]

Core Viewpoint - PMGC Capital LLC urges Alaunos Therapeutics, Inc. to accept a financing term sheet that could provide substantial capital and create significant shareholder value [1][4]. Group 1: PMGC Capital's Position - PMGC Capital holds a significant ownership position in Alaunos and is acting in the best interest of all shareholders [2]. - The proposed financing, introduced by PMGC Capital and led by a leading Wall Street bank, is described as a compelling opportunity for Alaunos [3]. - PMGC Capital emphasizes the importance of engaging with the bank to maximize long-term value for shareholders [4]. Group 2: Financing Details - The financing offer is characterized as non-toxic and well-structured, providing substantial capital to Alaunos [4]. - PMGC Capital commends Alaunos for maintaining a clean capital structure and prudent financial management during challenging market conditions [5]. Group 3: Company Background - PMGC Capital is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies across diverse markets [6]. - PMGC Holdings Inc. manages a diversified portfolio through strategic acquisitions and investments across various industries [7].

Core Insights - Northstrive Biosciences Inc. has initiated Phase II of its AI Development Program in collaboration with Yuva Biosciences, focusing on leveraging the MitoNova™ platform to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases [1][6] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., specializing in the development of innovative aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [3] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various sectors, including three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [4] Collaboration Details - The collaboration with YuvaBio involves using the MitoNova™ AI platform to virtually screen a large library of drug-like small molecules, predicting which candidates are most likely to promote mitochondrial health [2][6] - YuvaBio will analyze the screening results to identify opportunities for biological validation and compile a list of synthetic compounds aimed at muscle preservation and metabolic health [2]

Company Overview - PMGC Holdings Inc. is a diversified public holding company focused on strategic acquisitions and investments across various industries [7] - The company currently manages a portfolio consisting of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [7] Acquisition Details - PMGC has signed a non-binding Letter of Intent to acquire a U.S.-based electronics contract manufacturing company with over 40 years of operational history [1] - The target company generated approximately $699,000 in revenue and $173,000 in adjusted EBITDA in 2024 [3] Target Company Profile - The target company is a full-service provider of high-precision electronics manufacturing and assembly services, established in the 1980s [2] - It offers capabilities such as electrical and mechanical assembly, printed circuit card assembly, functional testing, and electronic component testing, serving a range of commercial and industrial clients [2] Strategic Rationale - The acquisition aligns with PMGC's strategy of acquiring fundamentally strong U.S.-based businesses with durable cash flow and growth potential [4] - PMGC management highlights the target's longstanding customer relationships and strong operational control as key advantages [4] Industry Context - The acquisition occurs amid a renewed national focus on revitalizing domestic manufacturing, supported by federal initiatives like the CHIPS and Science Act [5] - The U.S. electronics manufacturing services sector is positioned for growth as industries prioritize secure, localized, and high-quality production partners [5] - PMGC believes this transaction places the company at the intersection of this movement, providing exposure to a high-integrity operator within the ecosystem [5] Future Outlook - The closing of the acquisition is subject to customary conditions, including due diligence and corporate approvals [6] - This acquisition marks PMGC's second pending acquisition since April, indicating that its M&A strategy is actively progressing [9]

Core Insights - Northstrive Biosciences Inc. has completed a Phase I strategic research and literature synthesis for its first-in-class oral myostatin-engineered probiotic, EL-22, aimed at addressing muscle-wasting conditions [1][7] - The analysis, conducted with Yuva Biosciences, provided insights into EL-22's mechanism of action and its potential to meet critical needs in muscle-wasting conditions such as GLP-1-associated atrophy and age-related sarcopenia [1][7] Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on developing innovative aesthetic medicines [4] - The lead asset, EL-22, utilizes a myostatin-engineered probiotic approach to help preserve muscle during weight loss treatments, particularly with GLP-1 receptor agonists [4] Product Highlights - EL-22 employs a myostatin-engineered probiotic strategy to combat obesity-related muscle loss during weight loss treatments, offering a patient-friendly oral delivery method [2][4] - The product is designed to induce an immune response against myostatin, a key regulator of muscle growth, using genetically engineered Lactobacillus casei [2] Research Findings - The report highlights significant effects of EL-22 in mdx mice, including improvements in antibody production, serum creatine kinase levels, body weight, motor function, and muscle histology [7] - EL-22's unique oral vaccine approach distinguishes it from traditional systemic antibody or gene therapy methods, aiming to stimulate both mucosal and systemic immunity against myostatin [7] Market Positioning - With the rise of GLP-1 receptor agonists in obesity and diabetes treatment, EL-22 is strategically positioned to address the associated muscle loss concerns [7] - Northstrive plans to initiate a Phase 2 proof-of-concept trial targeting GLP-1 users and engage in regulatory discussions to advance EL-22 towards an IND filing in the U.S. [7]

Company Overview - PMGC Holdings Inc. has filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2025, with the SEC [1] - The company is well-capitalized with a strong balance sheet and a defined business focus [2] Operating Subsidiaries - NorthStrive Biosciences Inc. focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [2] - PMGC Research Inc. utilizes Canadian research grants and collaborates with universities to accelerate scientific discovery [3] - PMGC Capital LLC is a multi-strategy investment firm that seeks undervalued companies and assets to maximize returns [4] Strategic Growth Initiatives - The company is actively pursuing acquisitions of B2B businesses and assets to drive revenue growth and enhance shareholder value [2] - On April 16, 2025, PMGC announced a non-binding Letter of Intent to acquire a cash-flow-positive IT custom packaging company [5] Company Commitment - PMGC is committed to exploring opportunities across various sectors to maximize growth and value [6]